Market Closed -
Hong Kong S.E.
04:08:20 2024-05-14 am EDT
|
5-day change
|
1st Jan Change
|
0.051
HKD
|
+10.87%
|
|
+10.87%
|
+64.52%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
350.2
|
620
|
141
|
73.24
|
80.52
|
77.99
|
Enterprise Value (EV)
1 |
525.1
|
694.4
|
222.9
|
165.9
|
177.3
|
184.8
|
P/E ratio
|
32.6
x
|
-8.59
x
|
-0.71
x
|
-0.18
x
|
-0.24
x
|
-1.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.4
x
|
0.76
x
|
0.17
x
|
0.15
x
|
0.94
x
|
1.09
x
|
EV / Revenue
|
0.6
x
|
0.85
x
|
0.26
x
|
0.35
x
|
2.06
x
|
2.57
x
|
EV / EBITDA
|
12.8
x
|
-147
x
|
281
x
|
-14.9
x
|
-15
x
|
-56.8
x
|
EV / FCF
|
-2.7
x
|
-8.64
x
|
0.91
x
|
0.36
x
|
0.92
x
|
8.81
x
|
FCF Yield
|
-37%
|
-11.6%
|
110%
|
277%
|
108%
|
11.3%
|
Price to Book
|
0.47
x
|
0.71
x
|
0.2
x
|
0.26
x
|
-1.38
x
|
-0.68
x
|
Nbr of stocks (in thousands)
|
1,064,564
|
1,357,874
|
1,474,993
|
1,474,993
|
1,474,993
|
1,474,993
|
Reference price
2 |
0.3290
|
0.4566
|
0.0956
|
0.0497
|
0.0546
|
0.0529
|
Announcement Date
|
4/26/18
|
4/29/19
|
6/29/20
|
4/29/21
|
12/19/23
|
1/9/24
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
869.9
|
821.1
|
845.4
|
474.8
|
85.91
|
71.78
|
EBITDA
1 |
40.92
|
-4.72
|
0.793
|
-11.1
|
-11.85
|
-3.256
|
EBIT
1 |
35.38
|
-10.17
|
-4.736
|
-16.66
|
-17.13
|
-5.926
|
Operating Margin
|
4.07%
|
-1.24%
|
-0.56%
|
-3.51%
|
-19.94%
|
-8.26%
|
Earnings before Tax (EBT)
1 |
19.5
|
-48.05
|
-190.5
|
-425.8
|
-323.4
|
-43.16
|
Net income
1 |
10.18
|
-59.41
|
-193.7
|
-418.5
|
-330.4
|
-43.38
|
Net margin
|
1.17%
|
-7.23%
|
-22.91%
|
-88.13%
|
-384.58%
|
-60.43%
|
EPS
2 |
0.0101
|
-0.0532
|
-0.1338
|
-0.2837
|
-0.2240
|
-0.0294
|
Free Cash Flow
1 |
-194.3
|
-80.35
|
244.7
|
460
|
192.3
|
20.97
|
FCF margin
|
-22.34%
|
-9.78%
|
28.95%
|
96.88%
|
223.85%
|
29.21%
|
FCF Conversion (EBITDA)
|
-
|
-
|
30,863.38%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/26/18
|
4/29/19
|
6/29/20
|
4/29/21
|
12/19/23
|
1/9/24
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
175
|
74.4
|
81.9
|
92.7
|
96.7
|
107
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
4.274
x
|
-15.76
x
|
103.2
x
|
-8.349
x
|
-8.162
x
|
-32.8
x
|
Free Cash Flow
1 |
-194
|
-80.3
|
245
|
460
|
192
|
21
|
ROE (net income / shareholders' equity)
|
1.38%
|
-7.9%
|
-25.1%
|
-87.2%
|
-301%
|
49.9%
|
ROA (Net income/ Total Assets)
|
1.97%
|
-0.56%
|
-0.29%
|
-1.46%
|
-3.19%
|
-2.44%
|
Assets
1 |
517.2
|
10,639
|
67,264
|
28,722
|
10,342
|
1,776
|
Book Value Per Share
2 |
0.7000
|
0.6400
|
0.4700
|
0.1900
|
-0.0400
|
-0.0800
|
Cash Flow per Share
2 |
0.0300
|
0.0400
|
0.0100
|
0
|
0
|
0
|
Capex
1 |
72
|
15.7
|
0.09
|
0.08
|
0.22
|
0.03
|
Capex / Sales
|
8.28%
|
1.92%
|
0.01%
|
0.02%
|
0.26%
|
0.04%
|
Announcement Date
|
4/26/18
|
4/29/19
|
6/29/20
|
4/29/21
|
12/19/23
|
1/9/24
|
|
1st Jan change
|
Capi.
|
---|
| +64.52% | 8.68M | | +19.14% | 72.09B | | -3.34% | 23.88B | | +10.27% | 8.89B | | +12.67% | 8.46B | | -17.41% | 8.29B | | +9.65% | 4.9B | | +21.40% | 4.34B | | -1.41% | 3.98B | | -1.99% | 3.89B |
Pharmaceuticals Wholesale
|